Nevro Corp
NYSE:NVRO
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Nevro Corp
NYSE:NVRO
|
220.9m USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
189.2B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
172B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
137.5B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
135.6B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
133.3B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
58.7B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
47.1B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.8B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
36.7B USD |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Nevro Corp
Glance View
Nevro Corp. engages in the provision of medical devices. The company is headquartered in Redwood City, California and currently employs 945 full-time employees. The company went IPO on 2014-11-06. The firm has developed and commercialized the Senza spinal cord stimulation (SCS) system. SCS is a neuromodulation platform for the treatment of chronic pain, with the Senza Omnia platform, which is in addition to the Senza family of products. The Company’s solution for chronic pain includes 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain based on what it believes to be the best clinical evidence available. The advantages of its 10 kHz Therapy over traditional SCS include demonstrated superior efficacy data for both leg and back pain, paresthesia free pain relief for patients, anatomical lead placement for physicians, and ability to treat a broader group of chronic pain patients.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Nevro Corp is -27.8%, which is below its 3-year median of -15.8%.
Over the last 3 years, Nevro Corp’s Net Margin has increased from -34% to -27.8%. During this period, it reached a low of -36% on Jun 30, 2022 and a high of 0.7% on Dec 31, 2022.
